Investigated
What are the safety risks of inhibiting 15-PGDH?
Short answer
Image: ar.iiarjournals.org
Inhibiting 15-PGDH raises PGE2 and related prostaglandin signaling, which can aid tissue repair but may also stimulate cancer progression in susceptible tissues. Mouse and cell studies report increased pancreatic tumor expansion and colorectal liver metastasis, while other models show regenerative benefits. These findings establish important safety signals, not a quantified human risk profile.
The views on this question
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Alternative
Source weight 50%A more permissive reading emphasizes that elevated prostaglandin signaling is not inherently harmful: it can restore aged muscle, improve blood formation, repair gut and liver tissue, and protect the blood–brain barrier in animal studies. On this view, the danger is concentrated in patients with pre-existing or occult tumors rather than being a universal toxicity.
- Inhibition can improve regeneration after bone-marrow transplantation, ulcerative colitis, and partial hepatectomy in mouse models, suggesting potential benefits that may offset some risks in carefully selected settings.
- Studies in aging models report improved muscle, hematopoietic, gastrointestinal, and stem-cell function after targeting 15-PGDH.
- A 2025 mouse study reported that inhibiting 15-PGDH blocked blood–brain-barrier deterioration and protected against Alzheimer’s-related and traumatic brain injury outcomes.
- This benefit-oriented interpretation still leaves unresolved whether prolonged, systemic inhibition can preserve regeneration without increasing cancer risk.